Compare · BIIB vs IBRX
BIIB vs IBRX
Side-by-side comparison of Biogen Inc. (BIIB) and ImmunityBio Inc. (IBRX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BIIB and IBRX operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- BIIB is the larger of the two at $30.41B, about 3.8x IBRX ($8.04B).
- BIIB has been more active in the news (14 items in the past 4 weeks vs 3 for IBRX).
- BIIB has more recent analyst coverage (25 ratings vs 6 for IBRX).
- Company
- Biogen Inc.
- ImmunityBio Inc.
- Price
- -
- -
- Market cap
- $30.41B
- $8.04B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2015
- News (4w)
- 14
- 3
- Recent ratings
- 25
- 6
Biogen Inc.
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, BAN2401, BIIB092, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB111 and BIIB112 to treat ophthalmology related diseases; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and TMS-007 to treat acute neurology; BIIB074 and BIIB095 for neuropathic pain; and SB11 and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Bristol-Myers Squibb Company; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Ginkgo Bioworks; Capsigen Inc.; and Mirimus, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.
ImmunityBio Inc.
ImmunityBio, Inc., a clinical-stage immunotherapy company, develops cell and immune therapies to treat cancers and infectious diseases. The company develops Anktiva (N-803), an IL-15 superagonist and PD-L1 that activates natural killer and T effector cells in combination with chemo and trodelvy to treat cancers, such as merkel cell carcinoma, advanced pancreatic cancer, and advanced triple negative breast cancer; and an albumin-linked formulation of doxorubicin (Aldoxorubicin) to treat breast cancer, hodgkin lymphoma, SCLC, sarcoma, and glioblastoma. It also develops a memory T-cell cancer vaccine to deliver tumor-associated antigens and neoepitopes; and a human adenovirus 5 COVID-19 vaccine. The company was founded in 2014 and is based in San Diego, California.
Latest BIIB
- Synapticure Launches Groundbreaking Ataxia Care Program, Expanding Access to Specialized Neurology Nationwide
- Biogen Appoints Michael J. Parini as Chief Legal Officer
- LEQEMBI® Real-World LEADER Study Presented at AAIC® 2026 Finds Over 75% of Early Alzheimer’s Patients Enrolled in the Study Remained Stable and Nearly 7% Improved Over an Average of 17 Months of Treatment
- LEQEMBI® Real-World LEADER Study Presented at AAIC® 2026 Finds Over 75% of Early Alzheimer's Patients Enrolled in the Study Remained Stable and Nearly 7% Improved Over an Average of 17 Months of Treatment
- Biogen Presents Phase 2 CELIA Data at AAIC Demonstrating Meaningful Clinical Outcomes and Robust Tau Reduction with Diranersen in Early Alzheimer’s Disease
- FDA Approves LEQEMBI IQLIK® (lecanemab-irmb) Subcutaneous Injection as an Initiation Dose for Early Alzheimer’s Disease
- FDA Approves LEQEMBI IQLIK® (lecanemab-irmb) Subcutaneous Injection as an Initiation Dose for Early Alzheimer's Disease
- Biogen upgraded by Truist with a new price target
- Stoke Therapeutics Appoints Thomas McCauley, Ph.D., as Chief Scientific Officer
- LEQEMBI® Subcutaneous Autoinjector Clinical Data Supports Similar Efficacy and Safety to IV Formulation in Early Alzheimer’s Disease Presented at the Alzheimer’s Association International Conference® (AAIC®) 2026
Latest IBRX
- Director Cohen Cheryl sold $1,246,941 worth of shares (131,210 units at $9.50) as part of a pre-agreed trading plan and exercised 55,979 shares at a strike of $2.98, decreasing direct ownership by 37% to 125,386 units (SEC Form 4)
- Director Selecky Christobel sold $1,439,066 worth of shares (159,478 units at $9.02) as part of a pre-agreed trading plan and exercised 159,478 shares at a strike of $2.99 (SEC Form 4)
- Director Selecky Christobel exercised 96,722 shares at a strike of $2.94 and sold $871,216 worth of shares (96,722 units at $9.01) as part of a pre-agreed trading plan (SEC Form 4)
- Director Simon Barry J. sold $196,908 worth of shares (25,000 units at $7.88) as part of a pre-agreed trading plan, decreasing direct ownership by 0.88% to 2,802,788 units (SEC Form 4)
- SEC Form 4 filed by Director Blaszyk Michael D
- SEC Form 4 filed by Director Wendel Bruce
- SEC Form 4 filed by Director Maxwell Linda
- SEC Form 4 filed by Director Cohen Cheryl
- SEC Form 4 filed by Director Clark Wesley
- SEC Form 4 filed by Director Selecky Christobel